Liquidia Technologies Inc (LQDA)vsUnited Therapeutics Corporation (UTHR)
LQDA
Liquidia Technologies Inc
$75.49
-1.10%
HEALTHCARE · Cap: $6.33B
UTHR
United Therapeutics Corporation
$538.30
+0.40%
HEALTHCARE · Cap: $23.17B
Smart Verdict
WallStSmart Research — data-driven comparison
United Therapeutics Corporation generates 1000% more annual revenue ($3.17B vs $288.06M). UTHR leads profitability with a 40.6% profit margin vs 7.7%. UTHR trades at a lower P/E of 20.2x. UTHR earns a higher WallStSmart Score of 57/100 (C).
LQDA
Buy54
out of 100
Grade: C-
UTHR
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LQDA.
Margin of Safety
+2.4%
Fair Value
$487.70
Current Price
$538.30
$50.60 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 46.3%
Revenue surging 4159.0% year-over-year
Every $100 of equity generates 28 in profit
Keeps 41 of every $100 in revenue as profit
Strong operational efficiency at 41.7%
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
7.7% margin — thin
Elevated debt levels
Premium valuation, high expectations priced in
Expensive relative to growth rate
Revenue declined 1.6%
Earnings declined 12.2%
Comparative Analysis Report
WallStSmart ResearchBull Case : LQDA
The strongest argument for LQDA centers on Operating Margin, Revenue Growth, Return on Equity. Revenue growth of 4159.0% demonstrates continued momentum.
Bull Case : UTHR
The strongest argument for UTHR centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 40.6% and operating margin at 41.7%.
Bear Case : LQDA
The primary concerns for LQDA are EPS Growth, Profit Margin, Debt/Equity. A P/E of 419.0x leaves little room for execution misses. Debt-to-equity of 1.70 is elevated, increasing financial risk.
Bear Case : UTHR
The primary concerns for UTHR are PEG Ratio, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
LQDA profiles as a hypergrowth stock while UTHR is a declining play — different risk/reward profiles.
LQDA carries more volatility with a beta of 0.59 — expect wider price swings.
LQDA is growing revenue faster at 4159.0% — sustainability is the question.
UTHR generates stronger free cash flow (363M), providing more financial flexibility.
Bottom Line
UTHR scores higher overall (57/100 vs 54/100), backed by strong 40.6% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Liquidia Technologies Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and markets various products for the unmet needs of patients in the United States. The company is headquartered in Morrisville, North Carolina.
United Therapeutics Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?